Interdisciplinary symposium targets PI3K pathway
On October 4, the Center Scientific Council (CSC) hosted a symposium titled “Targeting the PI3K Pathway for Cancer Therapy,” the first of a quarterly series of workshops on emerging avenues of interdisciplinary research. Chaired by Lewis Cantley, PhD (BIDMC), the event featured presentations on PI3K/PTEN in breast cancer, identifying PI3K-activated tumors, mouse models for PI3K-driven tumors, and clinical trials of PI3K inhibitors (see agenda and videos below).
“Because the PI3K pathway is perturbed in many different cancers,” says Sarah Weiler, PhD, the DF/HCC deputy associate director for program coordination, “the Executive Committee and CSC recognized an opportunity for collaboration and cross-fertilization among disease programs and across disciplines.” Topics under consideration for future workshops include: “Vitamin D and Cancer Prevention” and “Obesity and Nutrition in Cancer.”
Overview of the PI3K pathway | Lewis Cantley, PhD | |
PI3K/PTEN in Breast Cancer | Ramon Parsons, MD, PhD | |
Identifying tumors with activated PI3K Pathway | Ralph Weissleder, MD, PhD MGH, Center for Molecular Imaging Research | |
| Pasi Janne, MD, PhD, DFCI, Dept. of Adult Oncology | |
| Todd Golub, MD, DFCI, Dept. of Pediatric Oncology | |
| Alexander Miron, PhD DFCI, Dept. of Cancer Biology | |
Mouse models for PI3K driven tumors | Thomas Roberts, PhD DFCI, Dept. of Cancer Biology | |
| Jeffrey A. Engelman, MD, PhD MGH, Dept. of Hematology/Oncology | |
Clinical Trials for PI3K inhibitors | Massimo Loda, MD DFCI, Pathology |
Video available in Windows Media Player format. If you click on the video links above and nothing happens, please download a copy of Windows Media Player for free.
